Sponsors (4)
The resolution promotes earlier detection, better veteran access, research, and education on prostate cancer—potentially reducing deaths and improving care—but raises real risks of overdiagnosis/overtreatment, added federal costs, and unnecessary testing if screening isn’t targeted by risk.
Men diagnosed with localized or regional prostate cancer (and their families) stand to benefit from earlier detection, which is associated with near‑100% survival for these stages.
Veterans with prostate cancer will gain improved access to precision oncology and specialized care through 21 VA Centers of Excellence focused on prostate cancer.
Patients, clinicians, and the public benefit from increased federal research funding (NIH/NCI and DoD programs) that supports advances in prevention, detection, and treatment over time.
Men (especially low‑risk men and older adults) face increased risk of overdiagnosis and overtreatment from expanded screening, which can lead to unnecessary procedures and lasting side effects.
Taxpayers and federal budget priorities may be affected as federal funds are allocated to prostate cancer research and VA programs, potentially crowding out other health or research needs.
Men may experience decreased autonomy and unnecessary testing if the emphasis on PSA/DRE screening is not tightly aligned with guideline‑based, risk‑targeted screening practices.
Based on analysis of 2 sections of legislative text.
Makes findings about prostate cancer prevalence, risk, screening, survival, and federal research funding and urges public and clinician education on screening and physician consultation.
Introduced October 6, 2025 by Michael Dean Crapo · Last progress October 6, 2025
Declares findings about the prevalence, risk factors, screening, survival rates, and federal research funding for prostate cancer and emphasizes the need for public and clinician education about screening and consulting with a physician. Notes current federal investments in cancer research and care, including FY2025 NIH and NCI appropriations, Department of Defense prostate cancer research funding, and VA precision oncology centers.